Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention

J. Zhang, K. Nkhata, A. A. Shaik, L. Wang, L. Li, Y. Zhang, L. A. Higgins, K. H. Kim, J. D. Liao, C. Xing, S. H. Kim, J. Lü

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Recent in vitro and in vivo preclinical studies have suggested that the Oriental herbal compound penta-1, 2, 3, 4, 6-O-galloyl-beta-D-glucose (PGG) is a promising chemopreventive agent for prostate cancer. Little is known of its safety for chronic chemoprevention use and virtually nothing is known of its in vivo responsive proteins in the target organ. Here we treated male C57BL/6 mice with daily oral administration of PGG at two dosages (1 and 2 mg per mouse) from 7 to 14 weeks of age and profiled proteomic patterns in the prostate with iTRAQ labeling and 2D LC-MS/MS analyses. While neither dose affected feed intake and body weight gain, the 2 mg dose (~80-100 mg per kg) led to a minor but statistically significant decrease of the weight of prostate and thymus. For proteomic profiling, five prostates were pooled from each group for protein extraction. Proteins were denatured, reduced, alkylated and digested to peptides. The peptides were labeled with iTRAQ reagents, mixed and subjected to 2D LC-MS/MS analyses. PGG consumption suppressed the abundance of oncoproteins (e.g., fatty acid synthase, clusterin) and up-regulated that of tumor suppressor proteins (e.g., glutathione S-transferase M), signifying changes that may contribute to prostate cancer risk reduction.

Original languageEnglish (US)
Pages (from-to)787-798
Number of pages12
JournalCurrent Cancer Drug Targets
Volume11
Issue number7
DOIs
StatePublished - Sep 1 2011

Fingerprint

Prostaglandins G
Chemoprevention
Proteome
Prostate
Proteomics
Prostatic Neoplasms
Clusterin
Tumor Suppressor Proteins
Fatty Acid Synthases
Neoplasms
Peptides
Proteins
Oncogene Proteins
Risk Reduction Behavior
Glutathione Transferase
Inbred C57BL Mouse
Thymus Gland
Weight Gain
Oral Administration
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Zhang, J. ; Nkhata, K. ; Shaik, A. A. ; Wang, L. ; Li, L. ; Zhang, Y. ; Higgins, L. A. ; Kim, K. H. ; Liao, J. D. ; Xing, C. ; Kim, S. H. ; Lü, J. / Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention. In: Current Cancer Drug Targets. 2011 ; Vol. 11, No. 7. pp. 787-798.
@article{c9e45c50d619400cb0eb0254d45c7b43,
title = "Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention",
abstract = "Recent in vitro and in vivo preclinical studies have suggested that the Oriental herbal compound penta-1, 2, 3, 4, 6-O-galloyl-beta-D-glucose (PGG) is a promising chemopreventive agent for prostate cancer. Little is known of its safety for chronic chemoprevention use and virtually nothing is known of its in vivo responsive proteins in the target organ. Here we treated male C57BL/6 mice with daily oral administration of PGG at two dosages (1 and 2 mg per mouse) from 7 to 14 weeks of age and profiled proteomic patterns in the prostate with iTRAQ labeling and 2D LC-MS/MS analyses. While neither dose affected feed intake and body weight gain, the 2 mg dose (~80-100 mg per kg) led to a minor but statistically significant decrease of the weight of prostate and thymus. For proteomic profiling, five prostates were pooled from each group for protein extraction. Proteins were denatured, reduced, alkylated and digested to peptides. The peptides were labeled with iTRAQ reagents, mixed and subjected to 2D LC-MS/MS analyses. PGG consumption suppressed the abundance of oncoproteins (e.g., fatty acid synthase, clusterin) and up-regulated that of tumor suppressor proteins (e.g., glutathione S-transferase M), signifying changes that may contribute to prostate cancer risk reduction.",
author = "J. Zhang and K. Nkhata and Shaik, {A. A.} and L. Wang and L. Li and Y. Zhang and Higgins, {L. A.} and Kim, {K. H.} and Liao, {J. D.} and C. Xing and Kim, {S. H.} and J. L{\"u}",
year = "2011",
month = "9",
day = "1",
doi = "10.2174/156800911796798959",
language = "English (US)",
volume = "11",
pages = "787--798",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

Zhang, J, Nkhata, K, Shaik, AA, Wang, L, Li, L, Zhang, Y, Higgins, LA, Kim, KH, Liao, JD, Xing, C, Kim, SH & Lü, J 2011, 'Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention', Current Cancer Drug Targets, vol. 11, no. 7, pp. 787-798. https://doi.org/10.2174/156800911796798959

Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention. / Zhang, J.; Nkhata, K.; Shaik, A. A.; Wang, L.; Li, L.; Zhang, Y.; Higgins, L. A.; Kim, K. H.; Liao, J. D.; Xing, C.; Kim, S. H.; Lü, J.

In: Current Cancer Drug Targets, Vol. 11, No. 7, 01.09.2011, p. 787-798.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention

AU - Zhang, J.

AU - Nkhata, K.

AU - Shaik, A. A.

AU - Wang, L.

AU - Li, L.

AU - Zhang, Y.

AU - Higgins, L. A.

AU - Kim, K. H.

AU - Liao, J. D.

AU - Xing, C.

AU - Kim, S. H.

AU - Lü, J.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Recent in vitro and in vivo preclinical studies have suggested that the Oriental herbal compound penta-1, 2, 3, 4, 6-O-galloyl-beta-D-glucose (PGG) is a promising chemopreventive agent for prostate cancer. Little is known of its safety for chronic chemoprevention use and virtually nothing is known of its in vivo responsive proteins in the target organ. Here we treated male C57BL/6 mice with daily oral administration of PGG at two dosages (1 and 2 mg per mouse) from 7 to 14 weeks of age and profiled proteomic patterns in the prostate with iTRAQ labeling and 2D LC-MS/MS analyses. While neither dose affected feed intake and body weight gain, the 2 mg dose (~80-100 mg per kg) led to a minor but statistically significant decrease of the weight of prostate and thymus. For proteomic profiling, five prostates were pooled from each group for protein extraction. Proteins were denatured, reduced, alkylated and digested to peptides. The peptides were labeled with iTRAQ reagents, mixed and subjected to 2D LC-MS/MS analyses. PGG consumption suppressed the abundance of oncoproteins (e.g., fatty acid synthase, clusterin) and up-regulated that of tumor suppressor proteins (e.g., glutathione S-transferase M), signifying changes that may contribute to prostate cancer risk reduction.

AB - Recent in vitro and in vivo preclinical studies have suggested that the Oriental herbal compound penta-1, 2, 3, 4, 6-O-galloyl-beta-D-glucose (PGG) is a promising chemopreventive agent for prostate cancer. Little is known of its safety for chronic chemoprevention use and virtually nothing is known of its in vivo responsive proteins in the target organ. Here we treated male C57BL/6 mice with daily oral administration of PGG at two dosages (1 and 2 mg per mouse) from 7 to 14 weeks of age and profiled proteomic patterns in the prostate with iTRAQ labeling and 2D LC-MS/MS analyses. While neither dose affected feed intake and body weight gain, the 2 mg dose (~80-100 mg per kg) led to a minor but statistically significant decrease of the weight of prostate and thymus. For proteomic profiling, five prostates were pooled from each group for protein extraction. Proteins were denatured, reduced, alkylated and digested to peptides. The peptides were labeled with iTRAQ reagents, mixed and subjected to 2D LC-MS/MS analyses. PGG consumption suppressed the abundance of oncoproteins (e.g., fatty acid synthase, clusterin) and up-regulated that of tumor suppressor proteins (e.g., glutathione S-transferase M), signifying changes that may contribute to prostate cancer risk reduction.

UR - http://www.scopus.com/inward/record.url?scp=80051721584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051721584&partnerID=8YFLogxK

U2 - 10.2174/156800911796798959

DO - 10.2174/156800911796798959

M3 - Article

C2 - 21762084

AN - SCOPUS:80051721584

VL - 11

SP - 787

EP - 798

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 7

ER -